Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019
Cited by 1,857 works. doi:10.1016/s0140-6736(18)32487-5
Authors
- David A. Palma
- Robert Olson
- Stephen Harrow
- Stewart Gaede
- Alexander V. Louie
- Cornelis J.A. Haasbeek
- Liam A. Mulroy
- Michael I. Lock
- George Rodrigues
- Brian Yaremko
- Devin Schellenberg
- Belal Ahmad
- Gwendolyn H.M.J. Griffioen
- Sashendra Senthi
- Anand Swaminath
- Neil Kopek
- Mitchell Liu
- Karen Moore
- Suzanne Currie
- Glenn S. Bauman
References
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
- Oligometastases.
- Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial